Clinical Trials Logo

Clinical Trial Summary

The investigators propose a comprehensive, multiomic study that will integrate longitudinal data associating changes in specific gut bacteria and host in response to prebiotic fiber supplementation. These data will guide the development of an integrative biological signature relating bacterial-derived metabolites with biological outcome in the host. The open sharing of data generated by the proposed research represents a significant public resource that will support and accelerate future novel studies.


Clinical Trial Description

Phenolics-rich prebiotic fiber has been correlated with a number of positive health outcomes, however their bioavailability is typically low. A large portion the gut microbiota metabolize these fibers releasing a range of phenolic acids, which are believed to be principle bioactive components driving reduction in disease risk. Despite this, little evidence exists linking specific gut bacteria with the metabolites they produce and the downstream biological effects that these compounds exert. With this study, the investigators propose to assemble a cohort of healthy individuals that will receive prebiotic supplementation, during comprehensive, longitudinal characterization of the microbiota and host changes with clinical markers and multiple omics assays. These multiomic data will then be integrated, generating unique biological signatures that define the role that microbial metabolites from specific bacteria play in host biological activity. To validate the biological function of these microbial metabolites, gnobiotic mice will be inoculated with the microbial strains identified. The newly identified metabolites will also be synthesized in vitro to demonstrate their structure, biological properties and applications. Through this study the investigators expect to gain a detailed and clear understanding of the physiological changes, at the mechanistic level, that occur in the microbiome and host in response to dietary supplementation with prebiotic fiber. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03925597
Study type Interventional
Source Stanford University
Contact Alessandra Celli, MS
Phone (650) 725-8491
Email alessandra.celli@stanford.edu
Status Recruiting
Phase N/A
Start date January 21, 2020
Completion date April 2025

See also
  Status Clinical Trial Phase
Completed NCT04043000 - Super 13 Pro & Prebiotics on the Human Intestinal Microflora N/A
Completed NCT01201577 - Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals Phase 1
Completed NCT04706858 - Integrative Personal Omics Profiling for Dynamic Molecular Phenotypes Monitoring During Fiber Supplementation N/A
Completed NCT03336385 - Prebiotic Supplementation and Intestinal Barrier Function in Elderly: a RCT N/A
Recruiting NCT03554694 - Gut-brain Axis, Brain Function, and Behaviour. N/A
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Completed NCT01549782 - Mixture of Prebiotics on Intestinal Microbiota of Patients Receiving Abdominal Radiotherapy. N/A
Completed NCT02118402 - Iron and Prebiotics Fortification in Kenyan Infants N/A
Completed NCT02679183 - Medically-Graded Honey Supplementation Formula To Preterm Infants Phase 0
Completed NCT03312660 - Effect of a Kefir Beverage on Immunity and Lipid Profile N/A
Completed NCT05584254 - Effects of β-glucans on Gut Permeability and Microbiota in Elderly N/A